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Abstract
Background: Sufficient data on outcome of patients with clinically and radiologically aggressive enchondromas and
atypical cartilaginous tumors (ACT) is lacking. We therefore analyzed both conservatively and surgically treated patients
with lesions, which were not distinguishable between benign enchondroma and low-grade malignant ACT based upon
clinical and radiologic appearance.
Methods: The series included 228 consecutive cases with a follow-up > 24months to assess radiological, histological, and
clinical outcome including recurrences and complications. Pain, satisfaction, functional limitations, and the musculoskeletal
tumor society (MSTS) score were evaluated to judge both function and emotional acceptance at final follow-up.
Results: Follow-up took place at a mean of 82 (median 75) months. The 228 patients all had comparable clinical and
radiological findings. Of these, 153 patients were treated conservatively, while the other 75 patients underwent
intralesional curettage. Besides clinical and radiological aggressiveness, most lesions were histologically judged as benign
enchondromas. 9 cases were determined to be ACT, while the remaining 7 cases had indeterminate histology. After
surgery, three patients developed a recurrence, and a further seven had complications of which six were related to
osteosynthesis. Both groups had excellent and almost equal MSTS scores of 96 and 97%, respectively, but significantly less
functional limitations were found in the non-surgery group. Further sub-analyses were performed to reduce selection
bias. Sub-analysis of histologically diagnosed enchondromas in the surgery group found more pain, less function, and
worse MSTS score compared to the non-surgery group. Sub-analysis of smaller lesions (< 4.4 cm) did not show significant
differences. In contrast, larger lesions displayed significantly worse results after surgery compared to conservative
treatment (enchondromas > 4.4 cm: MSTS score: 94.0% versus 97.3%, p = 0.007; pain 2.3 versus 0.8, p = 0.001). The majority
of lesions treated surgically was filled with polymethylmethacrylate bone-cement, while the remainder was filled with
cancellous-bone, without significant difference in clinical outcome.
Conclusion: Feasibility of intralesional curettage strategies for symptomatic benign to low-grade malignant
chondrogenic tumors was supported. Surgery, however, did not prove superior compared to conservative clinical and
radiological observation. Due to the low risk of transformation into higher-grade tumors and better functional results,
more lesions might just be observed if continuous follow-up is assured.
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Background
Enchondromas belong to the most frequently found car-
tilaginous bone lesions [1, 2]. Most enchondromas are
asymptomatic but malignant transformation into sec-
ondary chondrosarcoma is possible in 1–9% depending
on localization, pain, size, and radiologic presentation
[1–5]. Chondrosarcoma grade I is a low-grade malignant
tumor characterized by local aggressiveness leading to
destruction of cortical bone, increased pain, frequent
local recurrences, but usually does not develop metasta-
ses; consequently, it was renamed by the WHO to be an
‘atypical cartilaginous tumor’ (ACT) [1, 2, 6]. Several
reports discuss metastatic potential with a 2–8% prob-
ability depending on localization and recurrence [7, 8].
Histological and radiological differentiation between
clinically and radiologically aggressive enchondromas
and ACTs is extremely challenging and often not pos-
sible, so treatment depends mainly on the clinical behav-
ior without specific differentiation between both entities
[1, 4, 9–13]. Treatments include a wide spectrum from
wait and see to various surgical strategies without
significant evidence and consensus to support the dif-
ferent strategies [4, 14–17]. Lesions with high local
aggressiveness and pain are often surgically resected,
whereas smaller asymptomatic enchondromas are
most often treated conservatively [7, 10]. Neverthe-
less, there is no evidence if aggressive enchondromas
and ACTs should be treated surgically or not. Even
for ACTs, conservative strategies with radiographic
follow-up are proposed to prevent the overtreatment
and morbidity associated with surgery despite being a
low-grade malignant tumor [4, 9, 18].
Differences of clinical outcome between conservatively
and surgically treated patients are unknown and treat-
ment strategies remain highly individual. Therefore, the
study objective was to perform the thorough evaluation
of radiological and clinical outcomes in our series of 228
cases including recurrences, metastases, and functional
and emotional parameters of both groups to distinguish
potential differences and to improve decision making for
the treatment of these benign to low-grade malignant
bone tumors.
Materials and methods
All patients diagnosed with either aggressive enchon-
droma or ACT treated in our university orthopaedic
oncology outpatient clinic between 2005 and 2015 were
retrieved from a prospectively enrolled database and
retrospectively analyzed. Approval was given by the local
ethics committee of the University of Heidelberg,
Germany. Only aggressive lesions that were suspicious
for enchondroma or ACT with the need for continuous
follow-up in our oncology department were included.
Asymptomatic enchondromas without radiological signs
of aggressiveness and without recommended further
follow-up through our department were not included.
Cases initially suspicious for higher grade II or III chon-
drosarcomas (extensive cortical bone enlargement, large
interruption of the cortex, extensive invasion of the soft
tissues) were excluded. Further exclusion criteria were
follow-up shorter than 24 months (n = 92), and Ollier’s
disease (n = 16). Hence, 228 consecutive patients could
be included. Decision of conservative versus surgical
treatment was done individually as clinical and radio-
logic appearance would have justified both strategies.
Retrospective analysis of medical histories did not reveal
hard criteria for initial decision making as both groups
showed specific local pain and radiological signs of
aggressiveness (large lesion sizes; endosteal scalloping
with partial destruction of the cortical bone; similar cal-
cification patterns). Analysis of both alternatives with
conservative follow-up or immediate surgical treatment
had been discussed with the patients. After consider-
ation of individual advantages and disadvantages deci-
sion was made together with the patient, as there is still
no evidence and consensus in the literature, which
lesions should be treated surgically or not [4, 9, 14, 15,
18]. Radiological evaluation with x-rays and MRIs was
performed initially and at regular intervals between 6
and 24 months until final follow-up in both conserva-
tively and surgically treated cases. Images were reviewed
by a musculoskeletal radiologist sub-specialized in
orthopaedic oncology. Radiologic reports were well-doc-
umented with descriptions of the chondroid matrix, cal-
cification patterns, and destruction of cortical bone
(endosteal scalloping). Due to heterogeneous geometrical
configurations of the lesions, the size was evaluated by
measuring the longest diameter. CT-scans of the lesions
were only performed in limited cases. Pulmonary x-rays
and in the cases of histologically diagnosed ACTs an
additional pulmonary CT scan was obtained to rule out
metastases.
Histological evaluation was performed by the patholo-
gists of our university pathology department. Final diag-
nosis was confirmed in a consensus decision together
with the senior pathologist (GM). The main histological
criterion to distinguish ACT from enchondroma was
permeative infiltrative tumor growth with encapsulation
of lamellar bone trabeculae [19]. Further criteria were
hypercellularity, cellular atypia, myxoid areas, and cell
necrosis. Clinical evaluation with physical examination
was performed upon presentation to our musculoskel-
etal oncology outpatient clinic, which is responsible for
all orthopaedic tumor cases at our university. Patient
demographics and clinical histories were retrieved
including detailed information on surgical treatment,
recurrences, and complications. For systematic evalu-
ation of pain, patient satisfaction, and functional
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limitation at final follow-up, an additional telephone
interview was performed with a standardized question-
naire available for n = 59 patients in the surgery group
and n = 125 patients in the non-surgery group. Analog
scale ratings for pain and patient satisfaction from 0 to
10 were obtained. Clinical function was semi-quantita-
tively evaluated for the affected body part with the ox-
ford knee score [20], oxford hip score [21], foot and
ankle disability score [22], or quick disabilities of arm
shoulder and hand score [23]. Score values were recalcu-
lated into a 4-point grading with a range from 0 to 3
points (0 = no functional deficit; 3 = high disability with
poor function). Additionally, outcome was evaluated by
the well-established musculoskeletal tumor society
(MSTS) score combining functional parameters with
emotional acceptance and pain [24].
Descriptive statistics were calculated as mean and
range for numerical variables and for frequencies with
corresponding percentages for categorical variables. Stat-
istical analysis was performed for the outcome measures
“pain”, “satisfaction”, “functional limitations”, “MSTS
score”, “lesion size”, “complications”, and “recurrence”.
To compare the differences, Student T-tests, Mann-
Whitney-U-tests, and Kruskal-Wallis-tests were per-
formed depending on scale level and distribution of the
data. Statistical significance was assumed at a p-value <
0.05.
Results
The mean follow-up was 82 (median 75) months with a
range from 25 to 266 months for the whole series. Mean
(median) follow-up of the 153 conservatively treated
cases was 88 (79) months with a range from 25 to 266
months versus 70 (57) months with a range from 26 to
217 months for the 75 surgically treated cases. Localiza-
tions, demographics, and treatment strategies are pre-
sented in Table 1.
Surgically treated patients
Surgery was performed in 75 patients with extensive
intralesional curettage and additional use of a
high-speed burr. In 39 of these cases, additional H2O2
application was documented to cleanse the curetted le-
sion and reduce the risk for recurrence. Surgical strat-
egies could be divided into 5 sub-groups with different
frequencies depicted in Table 1. Most lesions were filled
with polymethylmethacrylate bone-cement (Fig. 1) pro-
viding immediate stability and destruction of potentially
remaining tumor cells at the margins due to the exother-
mic polymerization process when the bone-cement
hardens. Additional osteosynthesis (compound bone-
cement-plate-osteosynthesis) was used to increase stabil-
ity (Fig. 2).
Most surgically excised lesions (79%; n = 59) were his-
tologically described as benign enchondromas in the
final histological analyses. ACT was only diagnosed in
12% (n = 9) of surgically treated patients, and in a further
9% (n = 7) histology was not distinguishable between
enchondroma and ACT.
Open surgical incision biopsy was only performed in
20 cases due to ambiguous radiological appearance. Of
those, enchondroma was diagnosed in 15 cases, ACT in
4 cases, and in 1 case histology was not distinguishable
between enchondroma and ACT. The biopsied patients
were either radiologically followed (n = 7) or underwent
excision surgery (n = 13; n = 6 excision + bone-cement +
osteosynthesis; n = 5 excision + bone-cement; n = 2 exci-
sion + cancellous-bone + osteosynthesis). In all these
cases, final histology confirmed initial diagnosis from in-
cision biopsy. The remaining 62 surgically treated cases
received initial intralesional curettage without prior bi-
opsy. Incisional biopsy was avoided due to sufficient
radiologic diagnosis and to rule out sampling error in
histological evaluation and to spare a second approach.
No surgically treated patient was lost to follow-up.
Conservatively treated patients
The other 153 patients did not receive surgery but had
similar clinical and radiological findings as well as equal
mean age and demographics as surgically treated pa-
tients (Table 1). Lesions were defined as clinically and
radiologically aggressive enchondromas (Figs. 3 and 4).
Table 1 Patient demographics with localizations and way of
treatment
number percentage
gender (mean age)
total (47-years) 228 100
female (47-years) 154 68
male (47-years) 74 32
localization
femur 112 49
humerus 86 38
tibia 21 9
fibula 8 4
ulna 1 0.4
treatment strategy
non-surgical 153 67
surgery 75 33
curettage 2 1
curettage + bone-cement 34 15
curettage + bone-cement + osteosynthesis 27 12
curettage + cancellous-bone 6 3
curettage + cancellous-bone + osteosynthesis 6 3
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As surgical treatment was not performed, regular fo
llow-up was recommended and carried out in our ortho-
paedic oncology outpatient clinic. Conservatively follo
wed lesions remained qualitatively unchanged during
radiologic follow-up without significant increase of end-
osteal scalloping or instability. None of the conserva-
tively treated patients was lost to follow-up.
Lesion size
Mean lesion size of all cases was 4.4 ± 2.8 cm. Sizes of
the surgery and non-surgery group are depicted in Ta-
bles 2 and 3 and in Fig. 5. Conservatively treated pa-
tients showed a trend (p = 0.09) towards minimal (1%)
increase of radiological lesion size during follow-up.
Comparison of the lesion sizes of the surgical group
with the non-surgery group showed that for the
whole collective mean lesion size of surgically treated
lesions was slightly larger (5.2 ± 2.6 cm versus 4.0 ±
2.8 cm; (p = 0.002) (Fig. 5a). Sub-analysis of lesions
larger or smaller than the mean size of 4.4 cm was
additionally performed. Lesions < 4.4 cm (Fig. 5b)
showed a slightly larger mean lesion size in the sur-
gery group (p = 0.037), whereas lesions > 4.4 cm (Fig.
5c) did not show significant size differences in the
surgery and non-surgery group (p = 0.74). Hence,
comparison of these larger lesions > 4.4 cm will offer
best comparability with least possible selection bias
for both groups.
Comparison of lesion sizes of different localizations
within the surgery or non-surgery group did not show
statistically significant differences, neither in the surgical
group (p = 0.9), nor in the non-surgery group (p = 0.2).
Sizes of lesions with different histology were also not
significantly different (Table 2).
Considering different localizations in both groups, le-
sion size was only significantly larger for lesions in the
knee region, whereas there were no significant differ-
ences in lesions of the upper limb, the hip region and
Fig. 1 Surgical treatment at the proximal humerusTypical chondroid matrix (white arrows) is visible in ap x-ray (a) and coronal (c) and axial (d) T1
dotarem contrast-enhanced MRI. The decision to perform surgery was made due to local pain, lesion size and radiological signs of aggressiveness
with endosteal scalloping (red arrows). After rigorous intralesional curettage and use of a high-speed burr, the lesion was filled with
polymethylmethacrylate bone-cement (yellow arrows in b, e, and f).
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the ankle region between surgically and conservatively
treated cases of the whole collective (Table 3).
Lesion characteristics
Significant differences of the aggressiveness of the lesions
treated surgically or conservatively were not detectable.
All lesions showed at least some cortical scalloping, but
quantification was not possible due to highly heteroge-
neous appearance and localizations. The pattern of calcifi-
cation was also highly variable. Interestingly, lesions with
final histological diagnosis of ACT did not show more
scalloping nor more inhomogeneous calcification
patterns.
Recurrences
Three surgically treated patients showed recurrence. One
recurrence was found in a case with a lesion size < 4.4 cm
(1.5 cm) compared to 2 recurrences in cases with a lesion
size > 4.4 cm (5.5-6 cm). One patient had recurrence at
the proximal humerus 4 years after curettage. He received
revision surgery with implantation of bone-cement. Hist-
ology confirmed enchondroma recurrence. The 2nd case
with early enchondroma recurrence within one year re-
ceived re-curettage and no further recurrence was found.
Another patient with initial biopsy at the proximal tibia
and histological diagnosis of enchondroma did not receive
curettage. 6 years later, however, the lesion was growing
and radiologically suspicious. Curettage with implantation
of bone-cement confirmed ACT in final histology. An-
other 2 years later, contrast MRI revealed recurrence and
hence revision-surgery was performed with again intrale-
sional curettage and re-implantation of bone-cement.
Histology confirmed ACT again. Until final follow-up, no
further recurrence was found.
Complications
Seven out of 75 surgically treated patients had postoper-
ative fractures or revisions due to intra-articular screw
position (Table 4). Other complications (infection,
thrombosis, hematoma) were not noted. Lesions with
complications were not significantly larger (mean size
5.8 cm). Three out of 7 complications were found in
cases with a lesion size < 4.4 cm (3.5–3.8 cm) compared
to 4 complications in lesions with a size > 4.4 cm (5.0–
Fig. 2 Surgical treatment at the proximal tibiaTypical chondroid matrix (white arrows) and endosteal scalloping (red arrows) is visible in ap x-ray
(a) and coronal (b) and axial (c) T1 dotarem contrast-enhanced MRI. As a result of the large biomechanical stresses on the lesion location, a
compound osteosynthesis using polymethylmethacrylate bone-cement and a plate (yellow arrows in ap (d) and lateral (e) x-rays) was performed
after rigorous curettage and use of a high-speed burr.
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10.7 cm). Higher complication rate after osteosynthesis
was statistically significant (p = 0.01). Patients without
surgery had no fractures or other complications.
Clinical outcome
All patients showed excellent clinical outcomes, no
matter whether treated surgically or conservatively
with an MSTS score of 96% (mean 28.8 ± 1.6) and
97% (mean 29.2 ± 1.3), respectively (p = 0.13). For le-
sions < 4.4 cm the MSTS score was 29.3 ± 1.3 and
29.2 ± 1.3, respectively (p = 0.61). For lesions > 4.4 cm,
the MSTS score was significantly lower in surgically
treated patients (28.4 ± 1.7 and 29.2 ± 1.5, respectively;
p = 0.02). Surgically treated patients had significantly
more functional limitations with a mean score value
of 0.2 ± 0.5 versus 0.1 ± 0.3 in the non-surgery group
(p = 0.03) but considering different lesion sizes statis-
tical significance was lost (lesions < 4.4 cm: 0.2 ± 0.5
and 0.1 ± 0.3, respectively (p = 0.14); lesions > 4.4 cm
0.2 ± 0.6 and 0.1 ± 0.4, respectively (p = 0.14). Overall
patient satisfaction did not show significant differ-
ences between the surgery and the non-surgery group
(whole collective: 9.0 ± 1.4 versus 9.2 ± 1.2, p = 0.39;
lesions < 4.4 cm: 9.2 ± 1.3 versus 9.2 ± 1.2, p = 0.98; le-
sions > 4.4 cm: 8.8 ± 1.5 versus 9.2 ± 1.3, p = 0.35). For
those patients with final histological diagnosis of
enchondroma excluding ACT in the surgery group,
differences of clinical outcome were even more sig-
nificant (Tables 5, 6 and 7). Comparison of different
surgical treatment modalities did not reveal significant
differences in clinical outcome between bone-cement
filling and cancellous-bone filling. Surgery involving
adjunctive osteosynthesis showed worse patient satis-
faction compared to treatment without osteosynthesis
(mean 8.6 ± 1.5 versus 9.3 ± 1.3; p = 0.03), more pain
(mean 2.4 ± 2.0 versus 0.6 ± 1.4; p < 0.0001), and a
lower MSTS score of 94% vs. 98% (mean 28.1 ± 1.6
versus 29.3 ± 1.3; p = 0.001).
Discussion
We analyzed the outcome after both surgical and
conservative treatment of clinically and radiologically
aggressive benign to low-grade malignant chondro-
genic tumors of the long bones of the upper and
lower extremities. The surgically treated cases were
evaluated histologically, and diagnosed as benign
Fig. 3 Conservative treatment at the proximal humerusTypical chondroid matrix (white arrows) is visible in ap X-ray (a) and axial (b), coronal (c),
and sagittal (d) T1 dotarem contrast-enhanced MRI. Local pain, size and radiological signs of aggressiveness with endosteal scalloping (red
arrows) caused presentation and follow-up in our orthopaedic oncology department. The patient declined surgical excision, and was regularly
followed-up with MRI and x-ray to rule out significant tumor growth or increase in endosteal scalloping.
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enchondromas in the majority of the cases (n = 59),
while low-grade malignant ACT was diagnosed in
only a few cases (n = 9); in the remaining 7 cases, the
histology was unable to differentiate between ACT
and enchondroma, resulting from the known difficul-
ties in histologically differentiating both entities [1, 9,
10, 13, 19]. Comparison of all conservatively and sur-
gically treated lesions showed excellent clinical re-
sults, however, the functional limitations were
increased after surgical treatment. Surgically treated
patients with histological diagnosis of enchondroma
showed worse results for functional limitations, pain,
and the MSTS score compared to conservatively
treated patients. Sub-analysis of cases with larger
tumor size (> 4.4 cm) displayed significantly worse
clinical results with regard to pain and the MSTS
score in the surgery group compared to the conserva-
tive cohort. For surgically treated patients, the com-
plication rate has to be considered before carrying
out treatment. Seven of the 75 surgically treated pa-
tients had complications requiring revision surgery.
The revisions were necessary due to five peri-implant
fractures and two intra-articular screws, which sug-
gests lower complication risk in cases receiving the
more conservative approach without osteosynthesis
but otherwise non-inferior results – a finding, which
Fig. 4 Conservative treatment at the distal femurTypical chondroid matrix (white arrows) is visible in ap (a) and lateral (b) X-rays and coronal (c)
and axial (d) T1 dotarem contrast-enhanced MRI. Despite local pain, large lesion size, and endosteal scalloping (red arrows) surgery was
not performed.
Table 2 Lesion sizes depending on histological diagnosis
surgery group initial tumor size
mean in cm (±SD)
all (n = 75) 5.2 (±2.6)
histology (p = 0.7)
enchondroma (n = 59) 5.2 (±2.7)
ACT (n = 9) 5.7 (±2.5)
enchondroma or ACT (n = 7) 5.1 (±2.6)
Table 3 Lesion sizes of surgically and conservatively treated
tumors
surgery group
initial tumor size
mean in cm (±SD)
non-surgery group
initial tumor size
mean in cm (±SD)
significance
(p-value)
all (n = 228) 5.2 (±2.6) 4.0 (±2.8) p = 0.002
localization
upper limb
(n = 87)
5.2 (±2.5) 4.7 (±3.1) p = 0.4
hip region
(n = 31)
5.6 (±2.8) 4.0 (±2.4) p = 0.2
knee region
(n = 105)
5.2 (±2.7) 3.6 (±2.6) p = 0.01
ankle region
(n = 5)
4.9 (±3.4) 4.0 (±0.0) p = 0.8
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Fig. 5 Box plots comparing lesion sizes of the surgery and the non-surgery group for the whole collective including all lesion sizes (a) and for
lesions with tumor sizes < 4.4 cm (b) or > 4.4 cm (c)
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was statistically significant. This underscores higher
complication risks in cases treated with more sophis-
ticated surgical strategies [25–27].
We only found 3 recurrences in the 75 surgically
treated patients. Reasons for this might be the majority
of histologically benign lesions in the present study, lim-
ited follow-up time, but also surgical strategy. In surgi-
cally treated cases, common strategies were performed
to reduce the risk for recurrence [28] using rigorous cur-
ettage, additional administration of a high-speed burr,
the application of H2O2 and in most cases filling the
former tumor cavity with bone-cement, which has the
potential added effect of thermal necrosis of remaining
tumor cells due to the exothermic polymerization
process. The selected surgical treatment approach, in-
volving the extensive intralesional curettage instead of a
wider more aggressive resection is a well-reported
method, which results in improved functional outcome
and sufficient oncologic safety compared to more ag-
gressive surgical strategies [14, 16, 17, 29], which was
also supported by our low recurrence rate. We could
not find significant differences between the cases treated
surgically using bone-cement and cancellous bone, but
this may also be attributed to the lower number of cases
with cancellous-bone filling.
Interestingly, all recurrences occurred in cases with
initial histological diagnosis of benign enchondroma. Of
those, two again were histologically classified as enchon-
droma upon revision. In both cases, it cannot be con-
firmed that it was in fact a recurrence and not residual
tumor. The third recurrence was histologically classified
as ACT upon revision. This verifies the evident risk for
malignant transformation of initially benign enchondro-
mas with reported risks from 1 to 9%, [1–5] with the
need for long term follow-up of aggressive
enchondromas. Another explanation might be the
known difficulties of histological diagnosis.
We did not find transformation into higher grade
chondrosarcomas. Limited follow-up time but also se-
lection of lesions located in the long bones of the ex-
tremities without axial and pelvis tumors may explain
missing further transformations into higher grade
chondrosarcomas [1, 7]. Rigorous follow-up of radio-
logically aggressive lesions, however, seems crucial to
identify a potential transformation into ACT or even
higher-grade chondrosarcomas. The present study
cannot answer the question as to how often radio-
logical follow-up is required. We generally recom-
mend a first follow-up MRI after 3 to 6 months and
then every 12 months thereafter. A problem with the
conservative strategy might be patient compliance,
which is essential for sufficient oncological safety.
Ideally, follow-up should be carried out in specialized
orthopaedic oncology departments.
We only analyzed lesions of the long bones, since
more distally located enchondromas of the small bones
of the hands and feet show histological differences and
appear to have a lower potential for malignant trans-
formation or metastasizing compared to lesions in the
long bones [30, 31].
No metastases were noted in our collective during the
follow-up period of 7 years, however, later metastatic oc-
currence after this time cannot be ruled out. The risk for
later metastases should be extremely low, since pulmon-
ary metastases were only described in ACTs of the long
bones after local recurrence and transformation into
higher grade (grade II) chondrosarcomas [7, 32]. Based
on these experiences, we currently do not recommend
regular pulmonary imaging for these benign to low-grade
lesions unless we have reasonable suspicion for malignant
transformation or metastatic disease.
In 20 cases, we performed an initial incision biopsy
prior to intralesional curettage. In all cases, our initial
histological results were verified by final histology
after intralesional curettage, despite the reported risk
for sampling error and underestimation of the degree
of dedifferentiation [33, 34]. The only case showing a
possible misclassification was the one case with an
initial histological classification of enchondroma after
incisional biopsy and then recurrence 6 years later
showing evidence of ACT. The time-intervals, how-
ever, support a later malignant transformation from
enchondroma into ACT instead of misdiagnosis in
the biopsy. Hence, we still recommend incisional bi-
opsy if there is any doubt regarding malignancy. The
present study did not include cases with initial suspi-
cion for higher grade chondrosarcomas (extensive
cortical bone enlargement, large interruption of the
cortex, extensive invasion of the soft tissues). In such
Table 4 Complications after surgical treatment
fracture intra-articular
screw
total (n = 75) 5 2
Localization
upper limb 1 1
hip region 1 0
knee region 3 1
ankle region 0 0
histology
enchondroma 4 2
enchondroma or ACT 1 0
surgical strategy
curettage + bone-cement 1 0
curettage + bone-cement +
osteosynthesis
4 2
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cases, different treatment algorithms are required.
Here we always recommend initial biopsy and extrale-
sional tumor resection. For cases with radiological
diagnosis of aggressive enchondroma or ACT, where a
higher-grade malignancy seems radiographically un-
likely, the intralesional curettage strategy is favorable.
This is confirmed by the fact that we did not find
higher grade chondrosarcomas in the immediately
resected lesions in the present study.
It remains unclear, what is the most favorable treat-
ment option for clinically and radiologically aggressive
enchondromas and ACTs, since scientific evidence for
or against surgery is missing for these benign to
low-grade malignant tumors. To the best of our
knowledge, this is the first study with such a large
patient cohort to evaluate this collective and compare
surgical and non-surgical outcome. A potential selec-
tion bias of this retrospective study, however, has to
be discussed as an important limitation. Decision
making towards surgery or conservative follow-up
could not be controlled in the present study. This is
also reflected in the slightly, but statistically larger le-
sion sizes of the surgically treated cohort. To
minimize the selection bias between the surgery and
non-surgery groups, we performed further sub-group
analyses. We selected sub-groups with tumor sizes
smaller and larger than the mean size of the series
(4.4 cm). The sub-group with lesions larger than 4.4
cm offered the best comparability between the sur-
gery and the non-surgery groups, as in these cases
lesion size was not significantly different between
both groups. Histopathologic differences between the
surgery and the non-surgery groups cannot be ruled
out as most conservatively treated tumors did not
receive a biopsy. The conservatively treated lesions
did not show considerable increase in tumor size or
progression of scalloping until final follow-up. They
may be more comparable to the cases that were sur-
gically treated and histopathologically classified as
enchondromas.
Which chondroid lesions clearly need surgery and
which do not need surgery, cannot be sufficiently an-
swered by the present study, as we only differentiated the
lesions in respect to lesion size and histology. Further sub-
groups depending on initial clinical appearance and radio-
logical signs of aggressiveness could not be obtained as we
did not find significant differences in our highly selected
study population. Future studies should also compare sub-
groups of lesions with considerably different aggressive-
ness, to achieve objective data on which lesions will
benefit from surgery.
Table 5 Clinical outcome of enchondromas treated surgically or
conservatively without consideration of lesion size. Clinical score
values are shown as mean with standard deviation (±SD)
surgery group
enchondromas
(n = 51) (histologically
diagnosed)
non-surgery group
enchondromas
(n = 125) (radiologically
diagnosed)
significance
(p-value)
functional limitation score
rating
scale 0–3
0.2 (±0.5) 0.1 (±0.3) 0.036
pain score
rating
scale 0–10
1.6 (±2.1) 1.0 (±1.7) 0.024
satisfaction score
rating scale
0–10
8.8 (±1.5) 9.2 (±1.2) 0.057
MSTS score
rating scale
0–30
28.6 (±1.7) 29.2 (±1.3) 0.018
Table 6 Sub-group with lesion size < 4.4 cm: clinical outcome
of enchondromas treated surgically or conservatively. Clinical
score values are shown as mean with standard deviation (±SD)
surgery group
enchondromas
(n = 27) (histologically
diagnosed)
non-surgery group
enchondromas
(n = 87) (radiologically
diagnosed)
significance
(p-value)
functional limitation score
rating
scale 0–3
0.2 (±0.5) 0.1 (±0.3) 0.20
pain score
rating
scale 0–10
0.7 (±1.4) 1.1 (±1.8) 0.48
satisfaction score
rating
scale 0–10
9.1 (±1.4) 9.2 (±1.2) 0.84
MSTS score
rating
scale 0–30
29.2 (±1.3) 29.2 (±1.3) 0.87
Table 7 Sub-group with lesion size > 4.4 cm: clinical outcome
of enchondromas treated surgically or conservatively. Clinical
score values are shown as mean with standard deviation (±SD)
surgery group
enchondromas
(n = 24) (histologically
diagnosed)
non-surgery group
enchondromas
(n = 38) (radiologically
diagnosed)
significance
(p-value)
functional limitation score
rating
scale 0–3
0.3 (±0.6) 0.1 (±0.4) 0.06
pain score
rating
scale 0–10
2.3 (±2.1) 0.8 (±1.7) 0.001
satisfaction score
rating
scale 0–10
8.7 (±1.6) 9.2 (±1.3) 0.18
MSTS score
rating
scale 0–30
28.2 (±1.7) 29.2 (±1.5) 0.007
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This is the first study proving benefits in clinical and
functional outcome of cases conservatively followed as op-
posed to those treated surgically. Sampath et al. only rec-
ommend surgical therapy for actively growing lesions with
more than 6mm growth within 3 years [15]. Both good
clinical outcome and sufficient safety have been described
using this watch-and-wait strategy [4, 9, 17, 18]. From a
histological standpoint, surgery would not have been
needed to achieve sufficient oncological safety in our col-
lective, since the histology revealed that the majority of
our cases were benign enchondromas.
Conclusion
Our series of conservatively and surgically treated
enchondromas and ACTs displayed excellent clinical
outcomes. The conservative approach showed a signifi-
cantly better functional outcome compared to the surgi-
cal treatment, and appears to be a sufficiently safe
treatment option if strict clinical and radiographic
follow-up is assured. For the cases treated surgically, the
feasibility of intralesional curettage was confirmed but
overall results did not prove superiority compared with
only conservative wait and see strategy.
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